



PPL/CS/SE/88 /2012
14th August, 2012

To
The Bombay Stock Exchange Limited
Floor 25, P.J. Towers
Dalal Street
Mumbai 400 001
Kind Attn.: Mr. Gopal K. Iyer

The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai 400 051
Kind Attn.: Mr. Hari K.

Sub.: Corporate Announcement for the Outcome of the meeting of the Board of Directors of the Company held on 14th day of August, 2012,

Dear Sir,

This has in reference with our notice dated 6th August, 2012 regarding holding a meeting of the Board of Directors of the Company on Tuesday, the 14th August, 2012.


We would like to inform that the Board of Directors of the Company at their meeting held on today, i.e., Tuesday the 14th day of August, 2012, inter-alia, approved and take on record the Un-audited Financial Results of the Company for the quarter ended 30th June, 2012. The aforesaid Un-audited results have also reviewed by the Auditors of the Company.

Please find herewith the enclosed copy of the approved un-audited financial results of the Company for the quarter ended 30th June, 2012 and the Limited Review Report of the Auditor.

You are requested to please consider and take on record the above for your reference and records.

Thanking You

Yours Sincerely,
For **PLETHICO PHARMACEUTICALS LIMITED**


AMRISH CHOURASIA
COMPANY SECRETARY



Encl.: - As above

PLETHICO PHARMACEUTICALS LIMITED

Regd. Office : A.B. Road, Manglia - 453 771, Dist. - Indore (M.P.), +91-731-2806275, +91-731-2806271
Admn. Office : 37, Industrial Estate, Pologround, Indore 452 015 (M.P.) Tel.: +91-731-2422881/84
Fax : +91-731-2420838, 2421309
Corporate Office : Sabnam House, Plot No. A-15/16, Central Cross Road-B, M.I.D.C., Andheri (East),
Mumbai 400 093, INDIA Tel.: +91-22-66988301/302, Fax: +91-22-66988330/+91-22-66988300
Website : www.plethico.com **E-mail :** info@plethico.com, corporate@plethico.com

ON-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2012

Sl. No.	Particulars	Independent Financials						Consolidated Financials					
		3 Month Ended		6 Month Ended		Year Ended		3 Month Ended		6 Month Ended		Year Ended	
		31.03.2012	30.06.2011	30.06.2012	30.06.2011	31.12.2011	31.12.2011	31.03.2012	30.06.2011	30.06.2012	30.06.2011	31.12.2011	31.12.2011
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
1	Income from Operations	11322.66	10237.63	21830.29	23069.85	41260.83	38018.83	16387.95	46174.53	74065.83	80184.00	157594.05	157594.05
a)	Net Sales/Income from Operations	3162.32	(1453.49)	3708.48	1689.56	8381.26	5266.44	(752.86)	3947.53	673.20	673.20	8429.56	8429.56
b)	Other Operating Income	16482.98	9073.79	25559.77	24380.29	49879.57	42752.39	16840.81	45126.80	73668.63	79450.80	149294.49	149294.49
2	Expenses	4901.91	3931.54	10797.47	14772.86	21584.56	8397.73	8150.24	9725.81	17156.97	18666.50	32591.10	32591.10
a)	Cost of Materials Consumed	3697.52	3790.62	7668.14	725.78	5141.99	23228.54	14598.48	12938.42	37272.63	23610.00	59923.30	59923.30
b)	Purchase of Finished Goods	82.42	(26.37)	46.05	(278.44)	(587.49)	(14696.49)	609.88	687.94	(14926.61)	684.30	(1575.89)	(1575.89)
c)	(Increase) / Decrease in Stock in trade & work in progress	920.54	571.81	1708.15	1788.34	3739.51	3777.56	2089.98	3124.64	5957.56	5768.20	11162.70	11162.70
d)	Employees Cost	221.01	218.57	439.58	500.51	921.16	444.62	281.83	916.18	982.70	982.70	1860.10	1860.10
e)	Depreciation/Amortization	729.78	1125.10	1894.88	3576.68	7681.85	10631.15	6878.62	10545.06	17509.77	15362.30	36073.30	36073.30
f)	Other Expenses	10585.85	13840.27	2763.46	21085.73	33311.97	31087.87	33941.00	37473.70	65039.29	66041.30	136364.70	136364.70
3	Total Expenses	5899.78	(2575.48)	2974.30	3672.85	8178.17	12175.45	1128.07	8347.95	13003.52	14774.00	27768.93	27768.93
4	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-3)	2008	131	3.97	2.69	4.39	2.00	1.07	35.82	3.07	37.10	4.39	4.39
5	Profit / (Loss) from Ordinary Activities	5991.78	(2574.41)	2973.27	3675.27	11274.56	12177.44	1128.14	8383.97	13004.59	14881.10	27710.30	27710.30
6	Finance Costs	1290.03	983.54	2273.59	1138.61	7718.83	1570.29	1262.88	7115.34	2833.17	1401.20	8354.36	8354.36
7	Profit / (Loss) from Ordinary Activities after finance costs but before exceptional items (5+6)	4611.73	(3557.95)	749.68	2536.66	3555.73	10607.15	(133.74)	1268.63	1017.42	13409.90	19419.80	19419.80
8	Exceptional items	3749.48	3749.48	3749.48	3749.48	3749.48	3749.48	3749.48	3749.48	3749.48	3749.48	3749.48	3749.48
9	Profit / (Loss) from Ordinary Activities before tax (7+8)	4611.73	(208.47)	4003.26	2334.76	3555.73	10607.16	3615.74	1648.11	1437.90	1725.38	23214.28	23214.28
10	Tax expense	200.00	333.47	533.47	678.26	1019.23	801.61	544.17	154.07	1435.71	453.50	7827.70	7827.70
11	Net Profit / (Loss) from Ordinary Activities after tax (9+10)	4411.73	(541.94)	3469.79	1656.50	2536.50	9715.55	3071.57	1494.04	1294.19	1279.88	15386.58	15386.58
12	Extra Ordinary Items (net of tax expense)	(3555.00)	1672.50	(1882.50)	1.75	(6389.00)	(3555.00)	1672.50	(78.70)	(1812.50)	3.80	(6300.00)	(63

3/5

PARTICULARS OF SHAREHOLDINGS											
1 Public Shareholding											
a) Number of equity shares	442667	442667	442667	442667	442667	442667	442667	442667	442667	442667	442667
b) Percentage of Shareholding	13.00%	13.00%	12.99%	13.00%	12.99%	13.00%	12.99%	13.00%	12.99%	13.00%	12.99%
2 Promoter and Promoter Group Shareholding:											
a) Pledge/lien/encumbered											
- Number of Shares	27910659	27910659	25144565	27910659	25144565	27910659	25144565	27910659	25144565	27910659	25144565
- Percentage of Shares (as a % of total shareholding of promoter and promoter group)	94.18%	94.11%	84.81%	94.18%	84.83%	94.18%	84.83%	94.18%	84.83%	94.18%	84.83%
- Percentage of shares (as a % of the total share capital of the Company)	81.03%	81.87%	73.81%	81.93%	73.81%	81.93%	73.81%	81.93%	73.81%	81.93%	73.81%
b) Non-encumbered											
- Number of shares	1726350	1746850	4495435	1726350	4495435	1726350	4495435	1726350	4495435	1726350	4495435
- Percentage of Shares (as a % of total shareholding of promoter and promoter group)	5.82%	5.89%	15.17%	5.82%	15.17%	5.82%	15.17%	5.82%	15.17%	5.82%	15.17%
- Percentage of shares (as a % of the total share capital of the Company)	5.07%	5.13%	13.20%	5.07%	13.20%	5.07%	13.20%	5.07%	13.20%	5.07%	13.20%

EYESTUDY COMMENTS		3 Memo Read
Present at the beginning of the quarter		Nil
Present during the quarter		3
Disposed of during the quarter		Nil
Remaining unaccounted at the end of the quarter		Nil



4/5

Disclosure of Balance Sheet Means as per Chapter 41 (V) (b) of the Listing Agreement for the quarter ended 30-June-2012

Sr. No	Particulars	Independent Practitioner		Consolidated Financials	
		As on	As on	As on	As on
		30.06.2012	31.12.2011	30.06.2012	31.12.2011
A. EQUITY AND LIABILITIES					
1	Shareholders' funds				
a)	Share Capital	3406.67	3406.67	3406.67	3406.67
b)	Share Premium	56736.86	61182.47	140049.23	131079.43
c)	Reserves and Surplus	2000.00	2000.00	2000.00	2000.00
d)	Money Received against share warrants	62141.82	664109.54	145455.90	134686.19
2	Share application money pending allotment				
3	Minority Interest				
4	Non-current liabilities				
a)	Long-term borrowings	16000.52	15175.40	30205.77	31928.19
b)	Deferred tax liabilities (net)	1679.96	1595.83	-	-
c)	Other long-term liabilities	228.61	1524.60	228.61	1524.60
d)	Long-term provisions	17912.11	16894.99	30204.38	32482.79
5	Current liabilities				
a)	Short-term borrowings	15352.90	14015.81	15552.94	14415.81
b)	Trade payable	2379.20	1861.20	9775.10	5401.89
c)	Other current liabilities	64898.09	59531.13	78667.18	63345.10
d)	Short-term provisions	3113.36	2913.58	3693.20	2941.39
e)	Other non-current assets	85863.81	76122.72	99893.12	86680.81
f)	Other non-current liabilities	16599.44	16592.19	275839.40	253946.90
TOTAL-EQUITY AND LIABILITIES					
		139711.27	13367.25	917116.14	51085.20
B. ASSETS					
6	Non-current assets				
a)	Fixed Assets				
b)	Goodwill and Intangible Assets	80653.91	80653.91	15892.40	15892.40
c)	Investments			1242.70	3880.20
d)	Deferred tax assets (net)			6141.20	
e)	Long term loans and advances				
f)	Other non-current assets	91567.28	9843.16	107963.60	105751.19
7	Current Assets				
a)	Current investments	1097.55	2277.81	31543.90	18203.62
b)	Inventory	61235.19	59801.80	103261.10	97058.20
c)	Trade Receivables	3993.50	2753.24	6597.60	11040.40
d)	Cash and cash equivalents	30860.88	4943.11	23538.60	23538.60
e)	Short term loans and advances	25.03	50.07	191.50	211.80
f)	Other current assets	72352.16	69383.93	80764.80	180871.89
TOTAL ASSETS					
		165919.44	163514.19	275599.40	283946.90

1. The above Unaudited financial results for the quarter ended on 30th June, 2012 were approved at the meeting of the Board of Directors held on 14th Aug, 2012, who being approved and recommended by the Audit Committee.

2. The Statutory Auditors have carried out a limited review of the results for the quarter ended on 30th June, 2012.

3. The Company is engaged in a single segment viz. Pharmaceutical which is governed by the same set of risks and returns, therefore the Accounting Standard (AS-17) on "Segment Reporting" issued by ICAI, is not applicable.

4. Figures of the previous quarter / year wherever necessary have been rephrased and restated to conform to those of the current quarter.

5. The consolidated financial results comprise results of its wholly owned subsidiary Pablico International Ltd and Pablico Global Holdings P.V., Netherlands having different tax-jurisdiction subsidiaries particularly Pablico US Holding, KFT Hungary, Navro Ind. USA, and Synto Global UAE. The financial results of subsidiary companies have been reported and / or rephrased wherever necessary due to Indian GAAP audit conducted.

6. Extra ordinary items is related to unutilized exchange loss of Rs. 335500/- due to the settlement of outstanding Foreign Currency Convertible Bonds (FCCB) at the rate prevailing at the end of quarter.

For PABICO PHARMACEUTICALS LIMITED

 CHAIRMAN / CEO / MANAGING DIRECTOR

Date : 14.08.2012
 Place : India

5/5

N. P. GANDHI & Co.

Chartered Accountants

75, Podar Chambers, 3rd floor, S. A. Brelvi Street, Fort, Mumbai 400 001. Tel: 2261 7313 , 2261 7096 E-
nilesh@npgandhi.net

**Review Report to the Members of
Plethico Pharmaceuticals Limited**

We have reviewed the accompanying statement of un-audited financial results of **Plethico Pharmaceuticals Limited** for the period ended 30th June, 2012 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The Company has paid 62.75 Million as managerial remuneration to its directors as on December 2011, which is in excess of the limits under the Companies Act, 1956. Had the Company accounted for the remuneration in accordance with the Act, the Profit would have been higher by Rs 20.88 Million and Loans and Advances would have been higher by Rs 20.88 Million.

Based on our review, except for the matter described in the Basis of Qualified Conclusion, nothing has come to our attention that causes us to believe that the accompanying statement of un-audited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement

For N.P.Gandhi & Co.
Chartered Accountants

Nilesh Gandhi
Proprietor
M.No. 44294

Date:- 14th August, 2012

